Purification and Properties of the gp340 Component of Epstein–Barr Virus Membrane Antigen in an Immunogenic Form

References

1. Bowen B., Steinberg J., Laemmli U. K., Weintraub H. 1980; The detection of DNA binding proteins by protein blotting. Nucleic Acids Research 8:1–20
   [Google Scholar]
2. Crumpton M. J., Snary D. 1974; Preparation and properties of lymphocyte plasma membrane. Contemporary Topics in Molecular Immunology 3:27–56
   [Google Scholar]
3. De Schryver A., Klein G., Hewetson J., Rocchi G., Henle W., Henle G., Moss D. J., Pope J. H. 1974; Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). International Journal of Cancer 13:353–362
   [Google Scholar]
4. Edson C. M., Thorley-Lawson D. A. 1981; Epstein Barr virus membrane antigens: characterisation, distribution, and strain differences. Journal of Virology 39:172–184
   [Google Scholar]
5. Epstein M. A. 1976; Epstein–Barr virus - is it time to develop a vaccine program?. Journal of the National Cancer Institute 56:697–700
   [Google Scholar]
6. Epstein M. A., Achong B. G. (editors) 1979; The relationship of the virus to Burkitt’s lymphoma. In The Epstein–Barr Virus pp 321–337 Berlin, Heidelberg & New York: Springer-Verlag;
   [Google Scholar]
7. Epstein M. A., North J. R. 1982; Characterisation of Epstein–Barr virus antigens: towards a vaccine for malignancies associated with the virus. In Monoclonal Antibodies in Clinical Medicine pp 277–300 Edited by McMichael A. J., Fabre J. W. London: Academic Press;
   [Google Scholar]
8. Franklin S. M., North J. R., Morgan A. J., Epstein M. A. 1981; Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates. Journal of General Virology 53:371–376
   [Google Scholar]
9. Gergely L., Klein G., Ernberg I. 1971; Appearance of Epstein–Barr virus-associated antigens in infected Raji cells. Virology 45:19–21
   [Google Scholar]
10. Hager D. A., Burgess R. R. 1980; Elution of proteins from sodium dodecyl sulphate-polyacrylamide gels, removal of sodium dodecyl sulphate, and renaturation of enzymatic activity: Results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topiosomerase, and other enzymes. Analytical Biochemistry 109:76–86
    [Google Scholar]
11. Henle G., Henle W. 1979; The virus as the etiologic agent of infectious mononucleosis. In The Epstein–Barr Virus pp 297–320 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
    [Google Scholar]
12. Hoffman G. F., Lazarowitz S. G., Hayward S. D. 1980; Monoclonal antibody against a 250000-dalton glycoprotein of Epstein–Barr virus identifies a membrane antigen and a neutralising antigen. Proceedings of the National Academy of Sciences of the United States of America 77:2979–2983
    [Google Scholar]
13. Hudewentz J., Bornkamm G. W., Zur Hausen H. 1980; Effect of the diterpene ester TPA on Epstein–Barr virus antigen and DNA synthesis in producer and non-producer cell lines. Virology 100:175–178
    [Google Scholar]
14. Klein G. 1979; The relationship of the virus to nasopharyngeal carcinoma. In The Epstein–Barr Virus pp 339–350 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
    [Google Scholar]
15. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, London 227:680–685
    [Google Scholar]
16. Miller G., Shope T., Lisco H., Stitt D., Lipman M. 1972; Epstein–Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proceedings of the National Academy of Sciences of the United States of America 69:383–387
    [Google Scholar]
17. Mueller-Lantzsch N., Georg-Fries B., Herbst H., Zur-Hausen H., Braun D. G. 1981; Epstein–Barr virus strain and group specific antigenic determinants detected by monoclonal antibodies. International Journal of Cancer 28:321–327
    [Google Scholar]
18. North J. R., Morgan A. J., Epstein M. A. 1980; Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. International Journal of Cancer 26:231–240
    [Google Scholar]
19. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982a; Quantification of an EB virus-associated membrane antigen (MA) component. Journal of Virological Methods 5:55–65
    [Google Scholar]
20. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982b; Purified EB virus gp340 induces potent virus-neutralising antibodies when incorporated in liposomes. Proceedings of the National Academy of Sciences of the United States of America (in press)
    [Google Scholar]
21. Pearson G., Dewey F., Klein G., Henle G., Henle W. 1970; Relation between neutralization of Epstein–Barr virus and antibodies to cell-membrane antigens induced by the virus. Journal of the National Cancer Institute 45:989–995
    [Google Scholar]
22. Pearson G., Henle G., Henle W. 1971; Production of antigens associated with Epstein–Barr virus in experimentally infected lymphoblastoid cell lines. Journal of the National Cancer Institute 46:1243–1250
    [Google Scholar]
23. Qualtiere L. F., Pearson G. R. 1980; Radioimmune precipitation study comparing the Epstein–Barr virus membrane antigens expressed on P, HR-1 virus-superinfected Raji cells to those expressed on cells in a B95-8 virus-transformed producer culture activated with tumor-promoting agent (TPA). Virology 102:360–369
    [Google Scholar]
24. Strnad B. C., Schuster T., Klein R., Hopkins R. F. III, Witmer T., Neubauer R. H., Rabin H. 1982; Production and characterisation of monoclonal antibodies against the Epstein–Barr virus membrane antigen. Journal of Virology 41:258–264
    [Google Scholar]
25. Thorley-Lawson D. A. 1979; A virus-free immunogen effective against Epstein–Barr virus. Nature, London 281:486–488
    [Google Scholar]
26. Thorley-Lawson D. A., Edson C. M. 1979; The polypeptides of the Epstein–Barr virus membrane antigen complex. Journal of Virology 32:458–467
    [Google Scholar]
27. Thorley-Lawson D. A., Geilinger K. 1980; Monoclonal antibodies against the major glycoprotein (gp 350/220) of Epstein–Barr virus neutralise infectivity. Proceedings of the National Academy of Sciences of the United States of America 77:5307–5311
    [Google Scholar]